Merck Kgaa (MKGAF)

Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)

Merck KGaA is in advanced talks to acquire SpringWorks, whose portfolio could bolster Merck's oncology business amid patent expirations and competition.

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early treatment stages.

Japan’s Eisai Pharma formed a collaboration with SEED, a Pennsylvania biotech, to develop molecular glues for targeted protein degradation of disease-causing proteins. SEED is eligible to receive up to $1.5 billion in milestones plus royalties.

Merck KGaA (OTC: MKGAF) (OTC: 

Jiangsu Hengrui Pharma out-licensed global rights for its next-gen PARP1 inhibitor to Germany’s Merck KGaA for a $170 million upfront payment and up to $1.5 billion in milestones. Merck will have rights to manufacture and commercialize the drug.

Repligen Corporation (NASDAQ: RGEN) agreed to acquire Sweden-based privately-held Metenova. 

Merck KGa Germany (OTC: MKGAF) (OTC: MKKGY) reported 

The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen

RBC Capital Markets has downgraded Abcam PLC (NASDAQ: ABCM) from Outperform to Sector Perform with a price target of $22, 

Roche Holdings AG's  (OTC: RHHBY) Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS) 

Merck KGaA (OTC: MKGAF) and GlaxoSmithKline Plc (NASDAQ: GSK) have ended their $4 billion collaboration on cancer treatment, bintrafusp alfa. Merck said...

Nektar Therapeutics Inc (NASDAQ: NKTR) has entered into a new oncology clinical collaboration with Merck KGaA (OTC: MKGAF) and Pfizer Inc (NYSE...

Merck KGaA's (OTC: MKGAF) announced that a Phase 2 trial of bintrafusp alfa had been discontinued, as an independent data monitoring committee has determined the...

Sutro Biopharma Inc (NASDAQ: STRO) has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA...

Immutep Limited (NASDAQ: IMMP) has announced a new collaboration and supply agreement with Germany-based Merck KGaA (OTC: MKGAF) for a Phase 1/2a INSIGHT...

Vera Therapeutics Inc has priced its 4.35 million share IPO at $11 per share, well below its targeted range of $14 to $16, raising $47.58 million in gross proceeds. The...

England’s drug-cost watchdog has shown a cold-shoulder to Pfizer Inc (NYSE: PFE) and Merck KGaA’s (OTCMKTS: MKGAF) Bavencio (avelumab) as...

Palantir Technologies Inc. (NYSE: PLTR) is in the sweet spot of the heightened interest in companies involved in digital transformation. This is reflected in a slew of...